Raushan T. Kurmasheva, PhD :: Nationwide Children's Hospital, Columbus, Ohio

Raushan T. Kurmasheva, PhD

Raushan T. Kurmasheva, PhD

Contact Information

700 Children's Dr.
WA-5012
Columbus, OH 43205 [ map ]
PH: (614) 355-2993
E-mail Me

Biography

Gender:

  • Female

Languages Spoken:

  • English

Research Interests

Research Center:

Areas of Interest:

  • The research focus of the lab is identification of novel agents and drug combinations effective in children with CNS tumors (glioblastoma, medulloblastoma, ependymoma, low-grade glioma). We heterograft brain tumors from patients at diagnosis and at relapse, where appropriate, and establish PDX orthotopic models in scid-/- mice. We use the PDX orthotopic mouse model to determine whether orthotopic models differ significantly and substantially from the subcutaneous tumor by genomic analyses (gene expression, copy number variants, mutations), and also to test the effectiveness of different therapeutic agents using this model. Establishment of the bank of new PDX models of CNS tumors and their molecular characterization is another direction in the lab.

Education and Training

Postdoctoral Training

  • University of Arkansas for Medical Sciences
    Date Completed: 06/30/2004

Fellowship

  • St. Jude Children's Research Hospital
    Date Completed: 07/31/2007

Department:

  • Center for Childhood Cancer

Date of Appointment at Nationwide Children’s Hospital:

  • 05/01/2014

Publications

  • Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen C, Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Houghton P, Palanichamy K, Chakravarti A. FANCD2 is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3/FOXO1 Fusion Gene. Clin Cancer Res. 2014 Apr 30. [Epub ahead of print] PubMed ID: 24787670
  • Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Aug;61(8):1493-6. doi: 10.1002/pbc.25026. Epub 2014 Mar 24. PubMed ID: 24664981
  • Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 May;61(5):922-4. doi: 10.1002/pbc.24800. Epub 2013 Oct 26. PubMed ID: 24166988
  • Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Aug;61(8):1486-9. doi: 10.1002/pbc.24989. Epub 2014 Feb 20. PubMed ID: 24623675
  • Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA., Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Jun 9. doi: 10.1002/pbc.25099. [Epub ahead of print] PubMed ID: 24912408
Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000